Study study type PathologyT1T0Patientssample sizesROB Results

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

versus placebo
pembrolizumab alone
KEYNOTE-564 unpublished
  NCT03142334
RCTmetastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)pembrolizumabplaceboPatients (>=18yr), with histologically confirmed locoregional renal-cell carcinoma with a clear-cell component and with criteria for highr risk of recurrence.496 / 498NA
conclusif
  • suggested 46 % decrease in deaths (OS) (PE)
  • demonstrated 32 % decrease in RFS/DFS (PE)